Portfolio Companies

Published: 2022-05-18 BONESUPPORT ™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has received market authorizat...
Read more

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing no...
Read more

CHICAGO--(BUSINESS WIRE)--May 12, 2022-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for p...
Read more

Oslo, Norway, 12 May 2022 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces i...
Read more

25% Enrollment Achieved in CAHmelia-203 Study for Adult Classic CAH; On Track to Report Topline Data in 2H 2023 Debt Facility with Silicon Valley Bank Amended to Provide Up to ...
Read more

Results of recent studies demonstrate that Aro’s muscle-targeted Centyrin-siRNA conjugate robustly reduces toxic accumulation of muscle glycogen in a murine model of Pompe disea...
Read more

Targovax and Agenus have entered into a clinical collaboration agreement for the ONCOS-102 melanoma phase 2 multi-cohort trial ONCOS-102 will be tested in combination with th...
Read more

Launched Recorlev® and Gvoke® Kit Achieved Q1 net product revenue of $21.9M – a 33% increase from same period prior year on a pro forma basis Ended Q1 with&nbs...
Read more

2022-05-11 The following resolutions were passed at the annual general meeting (the “AGM”) of Vicore Pharma Holding AB (publ) on 11 May 2022. Adoption of income statemen...
Read more

Oslo, 11 May 2022 – Targovax ASA announces that members of its executive management team and key scientist are invited to present at upcoming conferences: 33rd ...
Read more